AI Article Synopsis
- Follicular lymphoma (FL) is a slow-growing type of small B-cell lymphoma that needs better prognostic tools beyond the current index commonly used.
- A study indicated that the expression patterns of specific markers like CD10, BCL6, Ki67, and FOXP1 might relate to how long patients remain progress-free when treated with chemotherapy-free therapies.
- The research focused on 90 patients treated with immunochemotherapy, revealing that high levels of Ki67 (≥30%) correlated with longer progression-free survival in those receiving R-CHOP treatment, suggesting its potential as a predictive biomarker in FL.
Article Abstract
Follicular lymphoma (FL) is a common, indolent small B-cell lymphoma. While the Follicular Lymphoma International Prognostic Index is widely used, reliable prognostic and predictive biomarkers are needed. A recent study suggested that architectural patterns of CD10, BCL6, and Ki67 expression may correlate with progression-free survival (PFS) in FL patients treated with chemotherapy-free regimens. We examined the prognostic and predictive utility of architectural patterns of CD10, BCL6, Ki67, and FOXP1 in 90 patients treated with immunochemotherapy (bendamustine-rituximab [BR] and R-cyclophosphamide, doxorubicin, vincristine, prednisone [CHOP]). We found that high follicular Ki67 (≥30%) was associated with longer PFS in the subgroup of patients treated with R-CHOP but not among those treated with BR. Validation of this biomarker may support routine use of Ki67 as a predictive marker in FL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2023.2214651 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!